capivasertib-话题@MedSci

#capivasertib#

7篇内容 | 1865人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2212031, encodeId=feed2212031cb, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a> <a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=首创AKT抑制剂capivasertib治疗三阴性乳腺癌III期临床失败！, objectType=article, longId=831983, objectId=f32a8319837d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240621/74fb233ab3a5484ba9735ca43bf05fa7-IvjuXAiznswK.jpg, objectUrl=/article/show_article.do?id=f32a8319837d, replyNumber=0, likeNumber=123, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=f32a8319837d, moduleTitle=首创AKT抑制剂capivasertib治疗三阴性乳腺癌III期临床失败！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f32a8319837d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2179863, encodeId=695d21e986376, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=【专家访谈】Capivasertib获批HR+/HER2-乳腺癌，临床使用时应关注哪些问题？, objectType=article, longId=808503, objectId=f3e38085039f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668017232524_4754896.png, objectUrl=/article/show_article.do?id=f3e38085039f, replyNumber=0, likeNumber=80, createdTime=2024-01-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=f3e38085039f, moduleTitle=【专家访谈】Capivasertib获批HR+/HER2-乳腺癌，临床使用时应关注哪些问题？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3e38085039f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2140420, encodeId=a6572140420f0, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>是一种口服可利用的小分子抑制剂，可以抑制所有三种AKT亚型。因此毒性还是相当大的！AKT的信号太上游了，安全性恐怕难以过关。与单独使用富马酸<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>相比，添加<a href='/topic/show?id=5215106305c8' target=_blank style='color:#2F92EE;'>#卡匹曲塞替#</a>治疗显著改善了<a href='/topic/show?id=7d0010630691' target=_blank style='color:#2F92EE;'>#激素受体阳性晚期乳腺癌#</a>患者的无进展生存期，这些患者在之前的内分泌治疗期间或之后出现疾病进展，可能合并<a href='/topic/show?id=fc9744059a' target=_blank style='color:#2F92EE;'>#CDK4/6抑制剂#</a>使用或未使用。腹泻和皮疹是接受卡匹曲塞替治疗的患者主要的不良事件。样本量大了以后，可能还会有更多的副作用出现<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a><a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>, objectTitle=NEJM：Capivasertib对HR阳性乳腺癌的治疗效果（CAPItello-291研究）, objectType=article, longId=774860, objectId=e56ae748600d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230601/1685640690838_4754896.jpeg, objectUrl=/article/show_article.do?id=e56ae748600d, replyNumber=0, likeNumber=148, createdTime=2023-06-02, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e56ae748600d, moduleTitle=NEJM：Capivasertib对HR阳性乳腺癌的治疗效果（CAPItello-291研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56ae748600d)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1594290, encodeId=097a159429079, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, objectType=article, longId=729208, objectId=e8d9e29208b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d9e29208b5, replyNumber=0, likeNumber=73, createdTime=2022-06-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d9e29208b5, moduleTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d9e29208b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594289, encodeId=6f6615942892d, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！, objectType=article, longId=729099, objectId=c01ae29099c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c01ae29099c1, replyNumber=0, likeNumber=82, createdTime=2022-06-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c01ae29099c1, moduleTitle=ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c01ae29099c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594288, encodeId=a86215942888b, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, objectType=article, longId=204950, objectId=4b6d204950d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b6d204950d0, replyNumber=0, likeNumber=91, createdTime=2020-12-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b6d204950d0, moduleTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b6d204950d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594287, encodeId=bfa2159428e20, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期, objectType=article, longId=187899, objectId=b0bc18e89904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0bc18e89904, replyNumber=0, likeNumber=78, createdTime=2020-02-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0bc18e89904, moduleTitle=Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0bc18e89904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594286, encodeId=df0f15942861f, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=AKT抑制剂capivasertib联合氟维司群显著改善HR+晚期乳腺癌无进展生存, objectType=article, longId=167942, objectId=55fd16e94251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55fd16e94251, replyNumber=0, likeNumber=79, createdTime=2019-06-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55fd16e94251, moduleTitle=AKT抑制剂capivasertib联合氟维司群显著改善HR+晚期乳腺癌无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55fd16e94251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594285, encodeId=888115942854b, content=<a href='/topic/show?id=a4644048b3' target=_blank style='color:#2F92EE;'>#capivasertib#</a>, objectTitle=ASCO 2019：AKT抑制剂capivasertib联合氟维司群显著改善HR+HER2-晚期乳腺癌结局, objectType=article, longId=167886, objectId=0bbd16e88668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbd16e88668, replyNumber=0, likeNumber=69, createdTime=2019-06-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbd16e88668, moduleTitle=ASCO 2019：AKT抑制剂capivasertib联合氟维司群显著改善HR+HER2-晚期乳腺癌结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbd16e88668)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

capivasertib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#三阴性乳腺癌# #capivasertib#

首创AKT抑制剂capivasertib治疗三阴性乳腺癌III期临床失败！

2024-06-28发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #capivasertib#

【专家访谈】Capivasertib获批HR+/HER2-乳腺癌，临床使用时应关注哪些问题？

2024-01-07发表于陕西省

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #capivasertib#是一种口服可利用的小分子抑制剂，可以抑制所有三种AKT亚型。因此毒性还是相当大的！AKT的信号太上游了，安全性恐怕难以过关。与单独使用富马酸#fulvestrant#相比，添加#卡匹曲塞替#治疗显著改善了#激素受体阳性晚期乳腺癌#患者的无进展生存期，这些患者在之前的内分泌治疗期间或之后出现疾病进展，可能合并#CDK4/6抑制剂#使用或未使用。腹泻和皮疹是接受卡匹曲塞替治疗的患者主要的不良事件。样本量大了以后，可能还会有更多的副作用出现#乳腺癌##氟维司群#

NEJM：Capivasertib对HR阳性乳腺癌的治疗效果（CAPItello-291研究）

2023-06-02发表于上海

智智灵药 (审核中...)

前往app查看评论内容

#capivasertib#

Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌

2022-06-14

智智灵药 (审核中...)

前往app查看评论内容

#capivasertib#

ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！

2022-06-12

智智灵药 (审核中...)

前往app查看评论内容

#capivasertib#

J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌

2020-12-30

智智灵药 (审核中...)

前往app查看评论内容

#capivasertib#

Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期

2020-02-14

智智灵药 (审核中...)

前往app查看评论内容

#capivasertib#

AKT抑制剂capivasertib联合氟维司群显著改善HR+晚期乳腺癌无进展生存

2019-06-11

智智灵药 (审核中...)

前往app查看评论内容

#capivasertib#

ASCO 2019：AKT抑制剂capivasertib联合氟维司群显著改善HR+HER2-晚期乳腺癌结局

2019-06-10

科室
- - 订阅+
  - 更多科室
工具
服务